Table 1.

Patients with moderate or strong staining ICCs

Patient number	NEUROPATHY	TUMOR	DRG neurons IgG	DRG neurons IgM	Schwann cells IgG	Schwann cells IgM	Motor neurons IgG	Motor neurons IgM	Clinical features
3	Sensory‐motor	OVARIAN	2	1	0	1	0	0	Rapidly progressive (over 1 month), predominantly distal, severe limb weakness plus ataxia. Very severe impairment of arthrokynetic and vibration sensation. Areflexia.EMG: Demyelinating features with severe axonal impairment and acute denervation
4	Sensory‐motor	LYMPHOMA	1	2	0	3a	0	0	Itch and paresthesia in 3 months. Gait unsteadiness and frequent falls. Mild distal weakness, severe vibration sensation impairment. Sudden progression to severe quadriparesis. Areflexia.EMG: severe sensory‐motor axonal polyneuropathy
7	Sensory‐motor	BREAST	0	0	0	3a	0	0	One week of weakness and distal paresthesia. Proximal (4/5) and distal (3/5) weakness. Severe vibration and arthrokynetic sensation impairment in all four limbs. Areflexia.EMG: axonal polyneuropathy. Seventeen cells and high protein content in CSF
33	Sensory‐motor	COLON	0	0	0	2	0	0	Mild gait impairment 1 year before. Progression in last weeks, with pan‐sensory impairment in four limbs. EMG: sensory‐motor axonal polyneuropathy. Dramatic improvement after tumor removal
34	Sensory‐motor	THYMOMA	3	1	0	2	2	0	Gait impairment, distal sensory disturbances, and distal weakness. EMG: demyelinating features, classified as CIDP. Improvement with steroids
19	Sensory	NSCLC	2a	0	1	0	0	0	Left hand paresthesia. Progression to all limbs, left side of face and trunk. Gait ataxia. Abolition of vibratory sensation in all four limbs. Arthrokinetic sensation impaired in left hand and foot. No weakness. Areflexia. First EMG, normal. Second EMG severe sensory neuronopathy
21	Sensory	TONSIL	0	0	1	2	0	0	Ataxia, paresthesia, vibration sensation impairment, and global areflexia.
30	Sensory	NSCLC	2a	0	0	0	0	0	Distal painful paresthesia in hands and feet. EMG: sensory axonal polyneuropathy
31	Sensory	PAROTID GLAND	0	1	1	0	1	2	Radicular pain in legs. Paresthesia in four limbs and trunk. Progression over 3 weeks to inability to walk. Severe impairment of joint position. High protein content in CSF

NSCLC, non‐small‐cell lung cancer; EMG, electromyography; CSF, cerebrospinal fluid.

^aIndicate sera used for antigen discovery with immunoprecipitation (IP) studies.